Does PALI pay dividends?

Palisade Bio Inc (PALI) does not currently pay a regular dividend.

What is PALI's market cap?

Palisade Bio Inc (PALI) has a market capitalization of $348.54M with a current stock price of $1.95.

Palisade Bio Inc (PALI)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$1.95

-0.05 (-2.50%)

Market Cap: $348.54M

Last updated: Sep 01, 2026 at 10:00 AM ET

Earnings

Performance (10Y)

Beat Rate

54%(13/24)

Avg Surprise

+15.59%

Streak

1 Q

Upcoming Estimates

Sep 30, 2026

EPS Consensus$-0.06

Range$-0.07 - $-0.05

7 analysts

EPS Revisions

30d

EPS Estimate Drift

90d ago$-0.05+9.5%

60d ago$-0.05+9.5%

30d ago$-0.06-7.5%

7d ago$-0.06-7.5%

Current$-0.06

Revenue Consensus

Range$0 - $0

6 analysts

Dec 31, 2026

EPS Consensus$-0.08

Range$-0.10 - $-0.05

7 analysts

Revenue Consensus

$357140

Range$0 - $500000

7 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.08	$-0.10 - $-0.05	-	-	7	-	-
Sep 30, 2026Sep 26EST	-	$-0.06	$-0.07 - $-0.05	-	-	7	2 1 30d	-
Jun 30, 2026Jun 26	$-0.05	$-0.05	$-0.07 - $-0.04	+0.00%	Beat	7	2 1 30d	+91.4%
Mar 31, 2026Mar 26	$-0.05	$-0.04	$-0.06 - $-0.01	-14.50%	Miss	6	0 1 30d	+90.3%
Dec 31, 2025Dec 25	$-0.06	$-0.03	$-0.05 - $-0.01	-97.17%	Miss	6	1 1 30d	+91.9%
Sep 30, 2025Sep 25	$-0.38	$-0.27	$-0.47 - $-0.03	-40.74%	Miss	3	1 1 30d	+83.6%
Jun 30, 2025Jun 25	$-0.58	$-0.56	$-0.62 - $-0.48	-3.57%	Miss	3	No revisions (30d)	+82.5%
Mar 31, 2025Mar 25	$-0.47	$-0.81	$-0.84 - $-0.78	+41.98%	Beat	2	No revisions (30d)	+89.8%
Dec 31, 2024Dec 24	$-0.69	N/A	-	+65.27%	Beat	3	0 2 30d	+89.3%
Sep 30, 2024Sep 24	$-2.32	$-3.35	$-3.63 - $-3.07	+30.75%	Beat	2	No revisions (30d)	+68.4%
Jun 30, 2024Jun 24	$-3.32	$-2.93	$-3.11 - $-2.75	-13.31%	Miss	2	No revisions (30d)	+58.2%
Mar 31, 2024Mar 24	$-4.59	$-3.75	$-3.75 - $-3.75	-22.40%	Miss	1	No revisions (30d)	+43.3%
Dec 31, 2023Dec 23	$-6.45	$-5.17	$-5.19 - $-5.16	-24.76%	Miss	2	No revisions (30d)	-199.7%
Sep 30, 2023Sep 23	$-7.35	$-6.15	$-6.19 - $-6.12	-19.51%	Miss	2	No revisions (30d)	+88.0%
Jun 30, 2023Jun 23	$-7.95	$-6.82	$-6.87 - $-6.78	-16.57%	Miss	2	No revisions (30d)	+91.2%
Mar 31, 2023Mar 23	$-8.10	$-9.90	$-9.97 - $-9.84	+18.18%	Beat	2	No revisions (30d)	+37.7%
Dec 31, 2022Dec 22	$6.47	$-2.43	$-2.47 - $-2.40	+366.26%	Beat	2	No revisions (30d)	+103.9%
Sep 30, 2022Sep 22	$-61.06	$-67.50	$-67.51 - $-67.49	+9.54%	Beat	2	No revisions (30d)	+67.4%
Jun 30, 2022Jun 22	$-90.00	N/A	-	+58.62%	Beat	1	No revisions (30d)	-2449.6%
Mar 31, 2022Mar 22	$-13.00	$-14.00	$-14.01 - $-13.99	+7.14%	Beat	2	No revisions (30d)	-196.1%
Dec 31, 2021Dec 21	$-165.75	$-180.00	$-180.01 - $-180.00	+7.92%	Beat	2	No revisions (30d)	-66200.0%
Sep 30, 2021Sep 21	$-187.27	$-270.00	$-270.00 - $-270.00	+30.64%	Beat	1	No revisions (30d)	-4165.8%
Jun 30, 2021Jun 21	$-3.53	N/A	-	N/A	Beat	-	-	+19.6%
Mar 31, 2021Mar 21	$-4.39	N/A	-	N/A	Beat	-	-	+0.0%
Dec 31, 2020Dec 20	$-0.25	N/A	-	N/A	Beat	-	-	+94.3%
Sep 30, 2020Sep 20	$-4.39	N/A	-	N/A	Beat	-	-	+0.0%
Jun 30, 2020Jun 20	$-4.39	N/A	-	N/A	Beat	-	-	+0.0%
Mar 31, 2020Mar 20	$-4.39	N/A	-	N/A	Beat	-	-	-1895.5%
Dec 31, 2019Dec 19	$-4.39	N/A	-	N/A	Beat	-	-	-1895.5%
Sep 30, 2019Sep 19	$-4.39	N/A	-	N/A	Beat	-	-	-3558.3%
Jun 30, 2019Jun 19	$-4.39	N/A	-	N/A	Beat	-	-	-448.8%
Mar 31, 2019Mar 19	$-0.22	N/A	-	N/A	Beat	-	-	+92.1%
Dec 31, 2018Dec 18	$-0.22	N/A	-	N/A	Beat	0	No revisions (30d)	-22.2%
Sep 30, 2018Sep 18	$-0.12	N/A	-	N/A	Beat	-	-	+33.3%
Jun 30, 2018Jun 18	$-0.80	N/A	-	N/A	Beat	-	-	+100.0%
Mar 31, 2018Mar 18	$-2.80	N/A	-	N/A	Beat	-	-	+99.9%
Dec 31, 2017Dec 17	$-0.18	$0.00	$0.00 - $0.00	N/A	Miss	0	No revisions (30d)	+100.0%
Sep 30, 2017Sep 17	$-0.18	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	+100.0%
Jun 30, 2017Jun 17	$-2160.00	N/A	-	+50.68%	Beat	-	-	-
Mar 31, 2017Mar 17	$-2580.00	$-3120.00	-	+17.31%	Beat	-	-	-
Dec 31, 2016Dec 16	$-4200.00	$-3120.00	-	-34.62%	Miss	-	-	-
Sep 30, 2016Sep 16	$-3900.00	$-2730.00	-	-42.86%	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-3.67	EV/EBITDA	0.57x
Price/FCF	-22.66x	FCF Yield	-4.41%
Profitability
Profit Margin	0.00%	Operating Margin	-2340.00%
ROE	-51.40%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	24.26x	Quick Ratio	24.26x
Trading Statistics
Beta	1.54	Avg Volume	1.58M
52-Week High	$2.86	52-Week Low	$0.53

Technical Indicators Dashboard

Moving Averages

SMA 10$2.06

SMA 20$2.08

SMA 50$2.02

SMA 200$1.94

EMA 10$2.05

EMA 20$2.05

EMA 50$2.02

EMA 200$1.84

MACD

Line: 0.01Signal: 0.02Hist: -0.02

ADX

ADX: 13.1+DI: 14.9-DI: 26.5

Aroon & PSAR

Aroon Up60.0

Aroon Down16.0

PSAR$2.22

Bollinger Bands

Upper Band$2.21

Lower Band$1.96

%B Position1205%(Upper)

Band Width-0.03

RSI (14-Day)

Neutral

44.7

Momentum Oscillators

Stoch %K28.2

Stoch %D44.4

Williams %R-93.1

ROC (10d)-9.3%

Momentum-0.20

CCI (20d)-209.8

MFI (14d)54.2

Volatility Measures

ATR (14d)$0.12(6.0%)

StdDev (20d)0.06

Hist Vol70.8%(High)

Volume Flow

VWAP$1.97

OBV156.3M

AD Line-142.8M

CMF (20d)0.087

Volume Metrics

Avg Vol (20d)1.6M

Vol Ratio1.0x

VWMA (20d)$2.08

Pivot Points

R3$2.20

R2$2.16

R1$2.08

Pivot Point$2.03

S1$1.96

S2$1.91

S3$1.83

Advanced Oscillators

TSI1.75

Ultimate Osc44.7

KST32.90

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$500,000	$0	$0	$0	$0	$0	$4,000	$0	$0	$0	$-250,000	$0
Cost of Revenue	$0	$0	N/A	$0	$0	$0	$2,000	$0	$0	$0	$54,000	$0
Gross Profit	$500,000	$0	N/A	$0	$0	$0	$2,000	$0	$0	$0	$-304,000	$0

Operating Expenses	$12.20M	$10.75M	$9.98M	$2.92M	$2.84M	$2.31M	$3.38M	$3.59M	$4.21M	$3.67M	$3.15M	$3.78M
R&D	$7.40M	$6.40M	$6.17M	$1.39M	$1.68M	$950,000	$2.08M	$2.14M	$2.63M	$2.21M	$1.37M	$2.10M
SG&A	$4.80M	$4.35M	$3.81M	$1.53M	$1.17M	$1.36M	$1.30M	$1.46M	$1.58M	$1.46M	$1.56M	$1.67M
Operating Income	$-11,698,000	$-10,748,000	$-9,981,000	$-2,922,000	$-2,843,000	$-2,310,000	$-3,382,000	$-3,593,000	$-4,211,000	$-3,673,000	$-3,154,000	$-3,778,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$2,000	$5,000	$0	$0	$3,000	$6,000	$2,000	$1,000	$4,000	$8,000
Income Before Tax	$-10,574,000	$-9,600,000	$-8,899,000	$-2,868,000	$-2,782,000	$-2,229,000	$-3,344,000	$-3,487,000	$-4,080,000	$-3,527,000	$-2,971,000	$-3,596,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-10,574,000	$-9,600,000	$-8,899,000	$-2,868,000	$-2,784,000	$-2,230,000	$-3,344,000	$-3,487,000	$-4,080,000	$-3,527,000	$-2,971,000	$-3,596,000

EBITDA	$-10,574,000	$-9,599,000	$-8,897,000	$-2,862,000	$-2,781,000	$-2,228,000	$-3,341,000	$-3,480,000	$-4,077,000	$-3,525,000	$-2,967,000	$-3,587,000
EBIT	$-10,574,000	$-9,599,000	$-8,897,000	$-2,863,000	$-2,782,000	$-2,229,000	$-3,341,000	$-3,481,000	$-4,078,000	$-3,526,000	$-2,967,000	$-3,588,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about PALI

News

Palisade Bio (PALI) CEO reallocates 176K shares in gifts

Palisade Bio (PALI) CEO and CFO, John David Finley, reallocated 176,800 shares of common stock through bona fide gifts on August 19, 2026. He transferred 88,400 shares from his direct ownership to FCW Investments, LLC, an entity he manages, resulting in direct holdings of 129,288 shares and indirect holdings of 88,451 shares. These transactions were not made under a Rule 10b5-1 trading plan.

Stock Titan•Aug 21, 2026 10:10 PM8/21/26•

Neutral

Palisade Bio Q3 EPS Decreased by Brookline Capital Markets

Brookline Capital Markets has reduced its Q3 2026 EPS estimate for Palisade Bio (NASDAQ: PALI) to a loss of $0.06 per share, anticipating continued losses through 2029. Despite this, Palisade Bio's recent quarterly results met analyst expectations with a loss of $0.05 per share and $0.50 million in revenue. The stock currently holds an average "Buy" rating with a $9.00 price target, and recent insider activity includes both purchases by a director and a sale by an insider for tax purposes.

MarketBeat•Aug 18, 2026 11:40 AM8/18/26•

Neutral

Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook

Palisade Bio, Inc. (PALI) announced that its existing cash reserves are sufficient to fund operations through key Phase 2 readouts expected in 2027–2028. The company is advancing its ASCENTRA-UC Phase 2 program and plans to initiate ASCENTRA-CD in late 2026 to early 2027. For Q2, Palisade Bio reported $0.5M in revenue and a net loss of $10.574M, with an EPS of -$0.05.

TradingView•Aug 17, 2026 11:12 AM8/17/26•

Somewhat-Bearish

FY2030 EPS Estimates for Palisade Bio Reduced by Analyst

Brookline Capital Markets has reduced its FY2030 EPS estimate for Palisade Bio (NASDAQ:PALI) from $0.41 to $0.39, while the full-year consensus remains a loss of $0.22 per share. The company recently reported quarterly earnings that met expectations, with an EPS loss of $0.05 and revenue of $0.50 million. Despite mixed analyst actions, Palisade Bio holds a consensus "Buy" rating with an average price target of $9.00.

MarketBeat•Aug 17, 2026 6:12 AM8/17/26•

Somewhat-Bearish

Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8

Maxim Group has reiterated its Buy rating for Palisade Bio (PALI.US) and maintained its target price at $8. This indicates continued confidence from the firm in the company's prospects.

Moomoo•Aug 15, 2026 5:41 AM8/15/26•

Bullish

Frequently Asked Questions About PALI

Does PALI pay dividends?: Palisade Bio Inc (PALI) does not currently pay a regular dividend.
What is PALI's market cap?: Palisade Bio Inc (PALI) has a market capitalization of $348.54M with a current stock price of $1.95.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In